SVF
Level B· Emerging Clinical EvidenceClinical Trial

Evaluation of Intravenously Delivered Allogeneic Mesenchymal Stem Cells for Treatment of Elbow Osteoarthritis in Dogs: A Pilot Study.

Olsen A., Johnson V., Webb T., Santangelo KS., Dow S., Duerr FM.

Clinical Trial with a reported sample of 13 on Osteoarthritis, published in Vet Comp Orthop Traumatol (2019) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Vet Comp Orthop Traumatol (2019)
Country
Germany
Reported sample size
13
PMID
30873568
DOI
10.1055/s-0039-1678547

Abstract (original English)

The aim of this study was to evaluate the safety and collect pilot data measuring clinical effects of intravenously administered, adipose-derived, culture-expanded, allogeneic mesenchymal stem cells in dogs with elbow osteoarthritis. Dogs ( n = 13) with naturally occurring elbow osteoarthritis received three intravenous doses of allogeneic canine mesenchymal stem cells via an open-label clinical trial. Primary outcome measures collected over a 6-month study period included objective gait analysis, accelerometry, owner questionnaires and joint fluid analysis. No acute adverse events were observed following repeated intravenous treatment with allogeneic mesenchymal stem cells. A significant improvement in mean client-specific outcome measure (CSOM) activity score and CSOM behaviour score was observed when pre-treatment values were compared with post-treatment values (day >28). In contrast, mean peak vertical force significantly decreased from baseline to post-treatment (>day 28). Weekly activity counts did not show a significant difference between baseline to post-treatment time points. Synovial fluid biomarkers did not change during treatment, and labelled mesenchymal stem cells were rarely detected in synovial fluid samples collected after mesenchymal stem cell administration. For dogs with naturally occurring elbow osteoarthritis, intravenous administration of mesenchymal stem

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies exist, but sample sizes, methodology, or follow-up remain limited, so conclusions are not firm.

How we grade evidence
AnimalsCells, CulturedDog DiseasesDogsFemaleForelimbMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsOsteoarthritis
Arm & ElbowSystemic / IVOsteoarthritis
View on PubMedDOI

Related research